Navigation Links
Canadian cold/flu breakthrough remedy undergoes NCI-sponsored trial in leukemia patients
Date:11/17/2008

Cancer patients with their weakened immune systems are particularly vulnerable when the cold and flu season hits. To help, the U.S. National Cancer Institute (NCI) is sponsoring a landmark trial to see whether a unique Canadian cold remedy COLD-FX can help.

The trial will examine whether using the #1 pharmacist recommended cold and flu fighting product in Canada ginseng extract COLD-FX reduces infections in chronic lymphocytic leukemia patients; enabling them to remain healthier to fight their disease. Cancer patients have weakened immune systems to begin with, usually as a result of chemotherapy or radiation.

The trial will be conducted by American cancer and infectious diseases experts at Wake Forest University School of Medicine in North Carolina. Wake Forest currently oversees approximately 150 cancer trials and is regarded as one of America's leading cancer research facilities.

The double-blind, placebo-controlled trial, involving 336 patients, was originally planned to include up to 19 U. S research sites. However, in approving the study, the NCI accelerated the process targeting completion over a single cold and flu season. To assist in recruitment, it also opened up its cancer trials support unit network of more than 1,500 cancer research sites across the U.S.

The NCI says on its website that the trial is important because both the cancer and its treatment, "can impair immune system functioning and markedly increase risk of infection, the most common complication" of chronic lymphocytic leukemia. "Two randomized, controlled trials have shown that an extract of North American Ginseng, called CVT-E002 (COLD-FX), can significantly reduce the risk of ARI [acute respiratory infection] in older adults," the website says.

In the battle against respiratory infections, there are few effective and economical treatment options. Apart from COLD-FX, there is no known clinical proven therapy for both prevention and treatment that naturally enhances the immune system to fight viral respiratory infections.

A recently reported three-year, multi-center study of COLD-FX, involving 780 participants, demonstrated that it cut infections by one-third in seniors taking the flu shot. The trial also showed that using a combo of COLD-FX and a flu shot provided greater protection than using the flu shot alone. This research complemented earlier clinical trials that formed the basis of Canada's regulatory approval of 400 milligrams of COLD-FX daily to reduce the frequency, severity and duration of cold and flu symptoms by boosting the immune system.


'/>"/>

Contact: Warren Michaels
warren.michaels@cvtechnologies.com
780-432-0022
CV Technologies Inc.
Source:Eurekalert

Related medicine news :

1. Natural Nutrition Canadian Subsidiary Signs $50.5 Million (CDN) Five Year European Distribution Contract
2. U of T professor first Canadian woman to win prestigious international science prize
3. Superbugs on the rise in Canadian hospitals, new Queens study shows
4. Leading Insurer Offers Education on How Supplemental Insurance Can Help Offset Challenging Economic Trends in Canadian Market
5. DIA 6th Canadian Annual Meeting Benefit and Risk Management: An Evolution in Progress
6. Safety Threat to Rochester Still Remains Despite Approval Of Canadian Pacifics Railroad Acquisition Of DM&E
7. Canadian Brand-Name Infant Formulas No Better than Private-Label Formulas
8. Clearwater's Canadian at-Home Dizziness Treatment Device Cleared by FDA
9. Canadian Company Sued for Defrauding Thousands of U.S. Consumers of Dietary Supplements
10. Canadian, German, Israeli, New Zealand, U.K and U.S. Companies Selected to Make Company Presentations at AdvaMed 2008
11. WellSpring Pharmaceutical Corp. Acquires Consumer Product Brands from McNeil Consumer Healthcare -- Deal Enhances US and Canadian Pharmaceutical Business
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has dedicated ... has implemented orthobiologic procedures as a method for treating his patients. The procedure ... doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of ... of the latter, setting the bar too high can result in disappointment, perhaps even ... progress toward their goal. , Research from PsychTests.com reveals that behind ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set of ... or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, Serenity ... event. , Trauma sufferers tend to feel a range of emotions, from depression, guilt, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was ... his family verbally and physically. , “When something upset him, he couldn’t control his emotions,” ... He would throw rocks at my other children and say he was going to kill ...
(Date:6/24/2016)... ... ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys are ... for this recognition are considered among the top 2 percent of lawyers practicing within ... of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. Bloom, ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Dehaier Medical Systems Ltd. (NASDAQ: ... and sells medical devices and wearable sleep respiratory products ... cooperation agreement with Hongyuan Supply Chain Management Co., Ltd. ... 20, 2016, to develop Dehaier,s new Internet medical technology ... will leverage Hongyuan Supply Chain,s sales platform to reach ...
(Date:6/24/2016)... According to a new market ... Needles, Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, ... of Purchase (Retail, Non-Retail) - Trends & Global Forecasts ... market for the forecast period of 2016 to 2021. ... by 2021 from USD 1.65 Billion in 2016, growing ...
(Date:6/24/2016)...  Arkis BioSciences, a leading innovator in the ... cerebrospinal fluid treatments, today announced it has secured ... led by Innova Memphis, followed by Angel Capital ... Arkis, new financing will accelerate the commercialization of ... of its in-licensed Endexo® technology. ...
Breaking Medicine Technology: